* Amgen and UCB submit biologics license application for
romosozumab to the FDA
The post BRIEF-Amgen and UCB submit biologics license application for romosozumab to the FDA appeared first on NASDAQ.
BRIEF-Amgen and UCB submit biologics license application for romosozumab to the FDA
